Indication
Acute Myeloid Leukemia
The Acute Myeloid Leukemia pipeline: 127 tracked drugs, 11 approved for this indication.
11 approved / phase 414 Phase 33 Phase 2/38 Phase 231 Phase 1/257 Phase 13 preclinical / unstaged
Compare the share prices of listed companies in Acute Myeloid Leukemia →
Total attributable cost
$4.3B
$190,305/patient
Drug spend
Not yet sourced
All stages, newly diagnosed (2026 incidence estimate) · US